{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T06:53:16Z","timestamp":1793083996318,"version":"4.5.0"},"reference-count":109,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.autrev.2025.103864","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T19:44:57Z","timestamp":1751571897000},"page":"103864","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"title":["Glucagon-Like Peptide-1 (GLP-1) receptor agonists in rheumatology: A review of current evidence and future directions"],"prefix":"10.1016","volume":"24","author":[{"given":"Emre","family":"Bilgin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Venerito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios P.","family":"Bogdanos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.autrev.2025.103864_bb0005","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct Target Ther"},{"issue":"10","key":"10.1016\/j.autrev.2025.103864_bb0010","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/nchembio.209","article-title":"A new glucagon and GLP-1 co-agonist eliminates obesity in rodents","volume":"5","author":"Day","year":"2009","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.autrev.2025.103864_bb0015","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3949\/ccjm.89a.21110","article-title":"The role of GLP-1 receptor agonists in managing type 2 diabetes","volume":"89","author":"Nachawi","year":"2022","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.autrev.2025.103864_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116150","article-title":"Efficacy and safety of GLP-1RAs for people with obesity: a systematic review based on RCT and Bayesian network meta-analysis","volume":"171","author":"Li","year":"2024","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"10.1016\/j.autrev.2025.103864_bb0025","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2014-000012","article-title":"Obesity and inflammatory arthritis: impact on occurrence, disease characteristics and therapeutic response","volume":"1","author":"Da\u00efen","year":"2015","journal-title":"RMD Open"},{"issue":"9","key":"10.1016\/j.autrev.2025.103864_bb0030","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/nrrheum.2011.107","article-title":"What\u2019s new in our understanding of the role of adipokines in rheumatic diseases?","volume":"7","author":"G\u00f3mez","year":"2011","journal-title":"Nat Rev Rheumatol"},{"issue":"5","key":"10.1016\/j.autrev.2025.103864_bb0035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0195123","article-title":"Obesity and response to anti-tumor necrosis factor-\u03b1 agents in patients with select immune-mediated inflammatory diseases: a systematic review and meta-analysis","volume":"13","author":"Singh","year":"2018","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.autrev.2025.103864_bb0040","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1136\/annrheumdis-2013-205094","article-title":"Overweight decreases the chance of achieving good response and low disease activity in early rheumatoid arthritis","volume":"73","author":"Sandberg","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.autrev.2025.103864_bb0045","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s40744-020-00215-6","article-title":"Obesity and psoriatic arthritis: a narrative review","volume":"7","author":"Kumthekar","year":"2020","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.autrev.2025.103864_bb0050","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.907750","article-title":"Obesity, inflammation, and immune system in osteoarthritis","volume":"13","author":"Nedunchezhiyan","year":"2022","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2025.103864_bb0055","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13098-024-01268-1","article-title":"Relationship between gout, hyperuricemia, and obesity\u2014does central obesity play a significant role?\u2014a study based on the NHANES database","volume":"16","author":"Mao","year":"2024","journal-title":"Diabetol Metab Syndr"},{"key":"10.1016\/j.autrev.2025.103864_bb0060","doi-asserted-by":"crossref","first-page":"112","DOI":"10.3389\/fphys.2018.00112","article-title":"Obesity, metabolic syndrome, and musculoskeletal disease: common inflammatory pathways suggest a central role for loss of muscle integrity","volume":"9","author":"Collins","year":"2018","journal-title":"Front Physiol"},{"key":"10.1016\/j.autrev.2025.103864_bb0065","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","article-title":"Glucagon-like peptide 1 (GLP-1)","volume":"30","author":"M\u00fcller","year":"2019","journal-title":"Mol Metab"},{"key":"10.1016\/j.autrev.2025.103864_bb0070","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.721135","article-title":"GLP-1 receptor agonists: beyond their pancreatic effects","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"10.1016\/j.autrev.2025.103864_bb0075","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1152\/physrev.00013.2014","article-title":"Physiology of proglucagon peptides: role of glucagon and GLP-1 in health and disease","volume":"95","author":"Sandoval","year":"2015","journal-title":"Physiol Rev"},{"issue":"6","key":"10.1016\/j.autrev.2025.103864_bb0080","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","article-title":"Biology of incretins: GLP-1 and GIP","volume":"132","author":"Baggio","year":"2007","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.autrev.2025.103864_bb0085","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/bph.15682","article-title":"Glucagon-like peptide-1 (GLP-1) signalling in the brain: from neural circuits and metabolism to therapeutics","volume":"179","author":"Kabahizi","year":"2022","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.autrev.2025.103864_bb0090","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/279530","article-title":"Effects of GLP-1 and incretin-based therapies on gastrointestinal motor function","volume":"2011","author":"Marathe","year":"2011","journal-title":"Exp Diabetes Res"},{"issue":"3","key":"10.1016\/j.autrev.2025.103864_bb0095","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1159\/000478872","article-title":"GLP-1\/GLP-1R Signaling in regulation of adipocyte differentiation and lipogenesis","volume":"42","author":"Chen","year":"2017","journal-title":"Cell Physiol Biochem"},{"key":"10.1016\/j.autrev.2025.103864_bb0100","doi-asserted-by":"crossref","DOI":"10.1177\/20420188231222367","article-title":"Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications","volume":"15","author":"Alharbi","year":"2024","journal-title":"Ther Adv Endocrinol Metab"},{"key":"10.1016\/j.autrev.2025.103864_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106320","article-title":"The anti-inflammatory and immunological properties of GLP-1 receptor agonists","volume":"182","author":"Bendotti","year":"2022","journal-title":"Pharmacol Res"},{"issue":"2","key":"10.1016\/j.autrev.2025.103864_bb0110","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.bbrc.2012.07.086","article-title":"Glucagon-like peptide-1 (GLP-1) induces M2 polarization of human macrophages via STAT3 activation","volume":"425","author":"Shiraishi","year":"2012","journal-title":"Biochem Biophys Res Commun"},{"issue":"9","key":"10.1016\/j.autrev.2025.103864_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamcr.2022.119300","article-title":"GLP-1 regulates exercise endurance and skeletal muscle remodeling via GLP-1R\/AMPK pathway","volume":"1869","author":"Wu","year":"2022","journal-title":"Biochim Biophys Acta, Mol Cell Res"},{"issue":"16","key":"10.1016\/j.autrev.2025.103864_bb0120","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1161\/CIRCULATIONAHA.124.067676","article-title":"Muscle mass and glucagon-like Peptide-1 receptor agonists: adaptive or maladaptive response to weight loss?","volume":"150","author":"Linge","year":"2024","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.autrev.2025.103864_bb0125","doi-asserted-by":"crossref","first-page":"H1120","DOI":"10.1152\/ajpheart.00210.2014","article-title":"AMPK activation by glucagon-like peptide-1 prevents NADPH oxidase activation induced by hyperglycemia in adult cardiomyocytes","volume":"307","author":"Balteau","year":"2014","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.autrev.2025.103864_bb0130","doi-asserted-by":"crossref","first-page":"6451902","DOI":"10.1155\/2018\/6451902","article-title":"ZP2495 protects against myocardial ischemia\/reperfusion injury in diabetic mice through improvement of cardiac metabolism and mitochondrial function: the possible involvement of AMPK-FoxO3a signal pathway","volume":"2018","author":"Li","year":"2018","journal-title":"Oxidative Med Cell Longev"},{"issue":"2","key":"10.1016\/j.autrev.2025.103864_bb0135","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3390\/medicina58020224","article-title":"The impact of GLP1 agonists on bone metabolism: a systematic review","volume":"58","author":"Daniilopoulou","year":"2022","journal-title":"Medicina"},{"key":"10.1016\/j.autrev.2025.103864_bb0140","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2017.00098","article-title":"The impact of glucagon-like Peptide-1 on bone metabolism and its possible mechanisms","volume":"8","author":"Zhao","year":"2017","journal-title":"Front Endocrinol"},{"issue":"1","key":"10.1016\/j.autrev.2025.103864_bb0145","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19010026","article-title":"Effects of glucagon-like Peptide-1 on oxidative stress and Nrf2 Signaling","volume":"19","author":"Oh","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.autrev.2025.103864_bb0150","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jot.2022.02.001","article-title":"Targeting the GLP-1\/GLP-1R axis to treat osteoarthritis: a new opportunity?","volume":"32","author":"Meurot","year":"2022","journal-title":"J Orthopaed Transl"},{"issue":"4","key":"10.1016\/j.autrev.2025.103864_bb0155","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.stemcr.2016.02.002","article-title":"Activation of GLP-1 receptor promotes bone marrow stromal cell osteogenic differentiation through \u03b2-catenin","volume":"6","author":"Meng","year":"2016","journal-title":"Stem Cell Rep"},{"key":"10.1016\/j.autrev.2025.103864_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2019.105732","article-title":"The protective effects of lixisenatide against inflammatory response in human rheumatoid arthritis fibroblast-like synoviocytes","volume":"75","author":"Du","year":"2019","journal-title":"Int Immunopharmacol"},{"issue":"8","key":"10.1016\/j.autrev.2025.103864_bb0165","first-page":"4800","article-title":"Liraglutide suppresses TNF-\u03b1-induced degradation of extracellular matrix in human chondrocytes: a therapeutic implication in osteoarthritis","volume":"11","author":"Mei","year":"2019","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.autrev.2025.103864_bb0170","author":"Exenatide"},{"key":"10.1016\/j.autrev.2025.103864_bb0175","author":"Liraglutide"},{"key":"10.1016\/j.autrev.2025.103864_bb0180","author":"Dulaglutide"},{"key":"10.1016\/j.autrev.2025.103864_bb0185","author":"Semaglutide"},{"key":"10.1016\/j.autrev.2025.103864_bb0190","author":"Lixisenatide"},{"issue":"2","key":"10.1016\/j.autrev.2025.103864_bb0195","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24021703","article-title":"GLP-1 receptor agonists in non-alcoholic fatty liver disease: current evidence and future perspectives","volume":"24","author":"Nevola","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.autrev.2025.103864_bb0200","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of Semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.autrev.2025.103864_bb0205","doi-asserted-by":"crossref","first-page":"777","DOI":"10.3233\/ADR-230181","article-title":"Clinical evidence for GLP-1 receptor agonists in Alzheimer\u2019s disease: a systematic review","volume":"8","author":"Liang","year":"2024","journal-title":"J Alzheimers Dis Rep"},{"issue":"7","key":"10.1016\/j.autrev.2025.103864_bb0210","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25073812","article-title":"GLP-1 receptor agonists: a new treatment in Parkinson\u2019s disease","volume":"25","author":"Kalinderi","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"13_Supplement","key":"10.1016\/j.autrev.2025.103864_bb0215","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S0735-1097(24)02381-7","article-title":"GLP-1 receptor agonists rising role in heart failure management: a systematic review and meta-analysis","volume":"83","author":"Ternes Caique","year":"2024","journal-title":"JACC"},{"issue":"2","key":"10.1016\/j.autrev.2025.103864_bb0220","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.rbmo.2019.04.017","article-title":"GLP-1 receptor agonists versus metformin in PCOS: a systematic review and meta-analysis","volume":"39","author":"Han","year":"2019","journal-title":"Reprod Biomed Online"},{"issue":"2","key":"10.1016\/j.autrev.2025.103864_bb0225","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1001\/jamaoncol.2023.5573","article-title":"GLP-1 receptor agonists and colorectal Cancer risk in drug-naive patients with type 2 diabetes, with and without overweight\/obesity","volume":"10","author":"Wang","year":"2024","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.autrev.2025.103864_bb0230","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/RHU.0000000000001949","article-title":"Glucagon-like peptide 1 receptor agonists in patients with inflammatory arthritis or psoriasis","volume":"30","author":"Karacabeyli","year":"2024","journal-title":"Jcr-J Clin Rheumatol"},{"key":"10.1016\/j.autrev.2025.103864_bb0235","first-page":"37","article-title":"GLP-1 based therapies and disease course of inflammatory bowel disease","author":"Villumsen","year":"2021","journal-title":"eClinicalMedicine"},{"issue":"10","key":"10.1016\/j.autrev.2025.103864_bb0240","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2024.0046","article-title":"GLP-1 receptor agonists and gastrointestinal adverse events","volume":"331","author":"Suissa","year":"2024","journal-title":"Jama-J Am Med Assoc"},{"issue":"10","key":"10.1016\/j.autrev.2025.103864_bb0245","doi-asserted-by":"crossref","first-page":"4386","DOI":"10.1111\/dom.15788","article-title":"Incidence and progression of diabetic retinopathy in patients treated with glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter 2 inhibitors: a population-based cohort study","volume":"26","author":"Lin","year":"2024","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"10.1016\/j.autrev.2025.103864_bb0250","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.tcm.2024.03.003","article-title":"The cardiovascular effects of GLP-1 receptor agonists beyond obesity and type 2 diabetes: an anti-atherosclerotic action","volume":"34","author":"Alexiadou","year":"2024","journal-title":"Trends Cardiovasc Med"},{"issue":"18","key":"10.1016\/j.autrev.2025.103864_bb0255","doi-asserted-by":"crossref","DOI":"10.21037\/atm-21-4162","article-title":"Hypoglycemia following the use of glucagon-like peptide-1 receptor agonists: a real-world analysis of post-marketing surveillance data","volume":"9","author":"Zhao","year":"2021","journal-title":"Ann Transl Med"},{"issue":"4","key":"10.1016\/j.autrev.2025.103864_bb0260","first-page":"403","article-title":"Glucagon-like Peptide-1 receptor agonists and thyroid Cancer: a narrative review","volume":"34","author":"De Ycaza","year":"2024","journal-title":"Thyroid"},{"key":"10.1016\/j.autrev.2025.103864_bb0265","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.927859","article-title":"Use of GLP-1 receptor agonists and occurrence of thyroid disorders: a Meta-analysis of randomized controlled trials","volume":"13","author":"Hu","year":"2022","journal-title":"Front Endocrinol"},{"issue":"7","key":"10.1016\/j.autrev.2025.103864_bb0270","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.autrev.2025.103864_bb0275","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1471-2288-14-43","article-title":"SYRCLE\u2019S risk of bias tool for animal studies","volume":"14","author":"Hooijmans","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.autrev.2025.103864_bb0280","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.autrev.2025.103864_bb0285","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"Bmj"},{"key":"10.1016\/j.autrev.2025.103864_bb0290","author":"OECD"},{"key":"10.1016\/j.autrev.2025.103864_bb0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2019.05.034","article-title":"Dulaglutide mitigates inflammatory response in fibroblast-like synoviocytes","volume":"74","author":"Zheng","year":"2019","journal-title":"Int Immunopharmacol"},{"issue":"7","key":"10.1016\/j.autrev.2025.103864_bb0300","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1002\/iub.2031","article-title":"Exenatide ameliorates inflammatory response in human rheumatoid arthritis fibroblast-like synoviocytes","volume":"71","author":"Tao","year":"2019","journal-title":"IUBMB Life"},{"issue":"Suppl. 10","key":"10.1016\/j.autrev.2025.103864_bb0305","article-title":"Treatment with the glucagon-likepeptide-1 analogue liraglutide is associated with amelioration of disease activity in a prospective cohort study of patients with inflammatory arthritis","volume":"65","author":"Sullivan","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"Suppl. 1","key":"10.1016\/j.autrev.2025.103864_bb0310","first-page":"A25","article-title":"Glucagon-like peptide-1: a key regulator of innate immune function with clinical efficacy in a range of inflammatory diseases","volume":"61","author":"Hogan","year":"2012","journal-title":"Diabetes"},{"key":"10.1016\/j.autrev.2025.103864_bb0315","first-page":"EP24","article-title":"New therapeutic opportunities shared by obesity, type 2 diabetes and rheumatoid arthritis","volume":"99","author":"Gavazova","year":"2024","journal-title":"Endocr Abstr"},{"issue":"8","key":"10.1016\/j.autrev.2025.103864_bb0320","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0308533","article-title":"Mortality and major adverse cardiovascular events after glucagon-like peptide-1 receptor agonist initiation in patients with immune-mediated inflammatory diseases and type 2 diabetes: a population-based study","volume":"19","author":"Karacabeyli","year":"2024","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.autrev.2025.103864_bb0325","article-title":"Effects of liraglutide among patients with psoriatic arthritis and obesity","volume":"21","author":"Nicolau","year":"2025","journal-title":"Reumatol Cl\u00edn (English Edition)"},{"issue":"1","key":"10.1016\/j.autrev.2025.103864_bb0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2025.103186","article-title":"Evaluating the causal effect of using glucagon-like peptide-1 receptor agonists on the risk of autoimmune diseases","volume":"19","author":"Sun","year":"2025","journal-title":"Diabetes Metab Syndr Clin Res Rev"},{"issue":"5","key":"10.1016\/j.autrev.2025.103864_bb0335","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1093\/rheumatology\/keae547","article-title":"A retrospective evaluation of glucagon-like peptide-1 receptor agonists in systemic lupus erythematosus patients","volume":"64","author":"Carlucci","year":"2025","journal-title":"Rheumatology"},{"issue":"suppl 9","key":"10.1016\/j.autrev.2025.103864_bb0340","article-title":"Glucagon-like Peptide-1 receptor agonist use and the risk of adverse cardiac and kidney outcomes among patients with systemic lupus erythematosus and lupus nephritis [abstract]","volume":"76","author":"Jorge","year":"2024","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.autrev.2025.103864_bb0345","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1002\/jcsm.13025","article-title":"Amelioration of inflammatory myopathies by glucagon-like peptide-1 receptor agonist via suppressing muscle fibre necroptosis","volume":"13","author":"Kamiya","year":"2022","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"9","key":"10.1016\/j.autrev.2025.103864_bb0350","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1002\/art.42540","article-title":"Lysosome-associated membrane protein 3 induces lysosome-dependent cell death by impairing autophagic caspase 8 degradation in the salivary glands of individuals with Sj\u00f6gren\u2019s disease","volume":"75","author":"Nakamura","year":"2023","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.autrev.2025.103864_bb0355","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/s41419-017-0217-y","article-title":"Glucagon-like peptide-1 receptor regulates endoplasmic reticulum stress-induced apoptosis and the associated inflammatory response in chondrocytes and the progression of osteoarthritis in rat","volume":"9","author":"Chen","year":"2018","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.autrev.2025.103864_bb0360","article-title":"The GLP-1 agonist, liraglutide, ameliorates inflammation through the activation of the PKA\/CREB pathway in a rat model of knee osteoarthritis","volume":"16","author":"Que","year":"2019","journal-title":"J Inflamm -London"},{"issue":"1","key":"10.1016\/j.autrev.2025.103864_bb0365","doi-asserted-by":"crossref","DOI":"10.1186\/s12891-024-07640-6","article-title":"Liraglutide, a glucagon-like peptide-1 receptor agonist, ameliorates inflammation and apoptosis via inhibition of receptor for advanced glycation end products signaling in AGEs induced chondrocytes","volume":"25","author":"Zhang","year":"2024","journal-title":"BMC Musculoskelet Disord"},{"issue":"1","key":"10.1016\/j.autrev.2025.103864_bb0370","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-05323-7","article-title":"Liraglutide, a glucagon-like peptide 1 receptor agonist, exerts analgesic, anti-inflammatory and anti-degradative actions in osteoarthritis","volume":"12","author":"Meurot","year":"2022","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.autrev.2025.103864_bb0375","first-page":"2081","article-title":"The protective effects of exenatide against AGEs-induced articular matrix degradation in human primary chondrocytes","volume":"11","author":"Tong","year":"2019","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.autrev.2025.103864_bb0380","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2020.108968","article-title":"The protective effects of dulaglutide against advanced glycation end products (AGEs)-induced degradation of type II collagen and aggrecan in human SW1353 chondrocytes","volume":"322","author":"Li","year":"2020","journal-title":"Chem Biol Interact"},{"issue":"1","key":"10.1016\/j.autrev.2025.103864_bb0385","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1080\/21691401.2019.1593996","article-title":"Lixisenatide attenuates advanced glycation end products (AGEs)-induced degradation of extracellular matrix in human primary chondrocytes","volume":"47","author":"Li","year":"2019","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"10.1016\/j.autrev.2025.103864_bb0390","first-page":"107","article-title":"Exploring antidiabetic drug targets as potential disease-modifying agents in osteoarthritis","author":"Fu","year":"2024","journal-title":"Ebiomedicine"},{"issue":"5","key":"10.1016\/j.autrev.2025.103864_bb0395","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1002\/jor.26050","article-title":"The anti-inflammatory effects of liraglutide in equine inflammatory joint models","volume":"43","author":"Scheike","year":"2025","journal-title":"J Orthop Res"},{"issue":"Suppl 9","key":"10.1016\/j.autrev.2025.103864_bb0400","article-title":"The cost-effectiveness of glucagon-like Peptide-1 receptor agonists (GLP1RAs) for patients with knee osteoarthritis and obesity","volume":"76","author":"Betensky","year":"2024","journal-title":"Arthritis Rheum"},{"issue":"17","key":"10.1016\/j.autrev.2025.103864_bb0405","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1056\/NEJMoa2403664","article-title":"Once-weekly semaglutide in persons with obesity and knee osteoarthritis","volume":"391","author":"Bliddal","year":"2024","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.autrev.2025.103864_bb0410","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/art.42754","article-title":"Weight loss induced by Antiobesity medications and all-cause mortality among patients with knee or hip osteoarthritis","volume":"76","author":"Wei","year":"2024","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.autrev.2025.103864_bb0415","article-title":"The impact of contemporary glucagon-like Peptide-1 receptor agonists on the onset, severity, and conversion to arthroplasty in hip and knee osteoarthritis. Orthopaedic","volume":"13","author":"Porto","year":"2025","journal-title":"J Sports Med"},{"issue":"2","key":"10.1016\/j.autrev.2025.103864_bb0420","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1093\/ajcn\/nqaa328","article-title":"Liraglutide after diet-induced weight loss for pain and weight control in knee osteoarthritis: a randomized controlled trial","volume":"113","author":"Gudbergsen","year":"2021","journal-title":"Am J Clin Nutr"},{"issue":"1","key":"10.1016\/j.autrev.2025.103864_bb0425","article-title":"Effect of weight loss and liraglutide on neutrophil gelatinase-associated lipocalin levels among individuals with overweight and knee osteoarthritis: exploratory analyses of a randomized controlled trial","volume":"7","author":"Stisen","year":"2025","journal-title":"Osteoarthritis Cartilage Open"},{"issue":"2","key":"10.1016\/j.autrev.2025.103864_bb0430","doi-asserted-by":"crossref","DOI":"10.1016\/j.ocarto.2022.100255","article-title":"Changes in physical activity during a one-year weight loss trial with liraglutide vs placebo in participants with knee osteoarthritis: secondary analyses of a randomised controlled trial","volume":"4","author":"Bartholdy","year":"2022","journal-title":"Osteoarthritis Cartilage Open"},{"issue":"9","key":"10.1016\/j.autrev.2025.103864_bb0435","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1136\/ard-2023-223845","article-title":"Glucagon-like peptide-1 receptor agonists as a disease-modifying therapy for knee osteoarthritis mediated by weight loss: findings from the Shanghai osteoarthritis cohort","volume":"82","author":"Zhu","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.autrev.2025.103864_bb0440","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1080\/14656566.2024.2391524","article-title":"The impact of approved anti-obesity medications on osteoarthritis","volume":"25","author":"Baser","year":"2024","journal-title":"Expert Opin Pharmacother"},{"issue":"10","key":"10.1016\/j.autrev.2025.103864_bb0445","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1016\/j.arth.2024.06.008","article-title":"The five-year incidence of progression to osteoarthritis and Total joint arthroplasty in patients prescribed glucagon-like peptide 1 receptor agonists","volume":"39","author":"Lavu","year":"2024","journal-title":"J Arthroplasty"},{"issue":"3","key":"10.1016\/j.autrev.2025.103864_bb0450","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.arth.2023.12.023","article-title":"Semaglutide use prior to Total hip arthroplasty results in fewer postoperative prosthetic joint infections and readmissions","volume":"39","author":"Magruder","year":"2024","journal-title":"J Arthroplasty"},{"issue":"11","key":"10.1016\/j.autrev.2025.103864_bb0455","doi-asserted-by":"crossref","DOI":"10.1016\/j.arth.2023.05.071","article-title":"Does Semaglutide use decrease complications and costs following Total knee arthroplasty?","volume":"38","author":"Magruder","year":"2023","journal-title":"J Arthroplast"},{"issue":"7","key":"10.1016\/j.autrev.2025.103864_bb0460","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1080\/17581869.2024.2402214","article-title":"Dual effects of dulaglutide on glycemic control and knee osteoarthritis pain in elderly patients with type 2 diabetes","volume":"14","author":"Samajdar","year":"2024","journal-title":"Pain Manag"},{"issue":"10","key":"10.1016\/j.autrev.2025.103864_bb0465","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1002\/pds.5252","article-title":"Sodium-glucose cotransporter-2 inhibitors and the risk of gout: a Danish population based cohort study and symmetry analysis","volume":"30","author":"Lund","year":"2021","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"9","key":"10.1016\/j.autrev.2025.103864_bb0470","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1007\/s10067-023-06647-z","article-title":"Sodium glucose cotransporter 2 inhibitors and gout risk: a sequence symmetry analysis","volume":"42","author":"Wood","year":"2023","journal-title":"Clin Rheumatol"},{"issue":"11","key":"10.1016\/j.autrev.2025.103864_bb0475","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.clinthera.2024.06.021","article-title":"SGLT2 inhibitors, but not GLP-1 receptor agonists, reduce incidence of gout in people living with type 2 diabetes across the therapeutic Spectrum","volume":"46","author":"Preston","year":"2024","journal-title":"Clin Ther"},{"issue":"10","key":"10.1016\/j.autrev.2025.103864_bb0480","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1007\/s11606-024-08793-9","article-title":"Empagliflozin and risk of incident gout: analysis from the EMPagliflozin comparative effectiveness and SafEty (EMPRISE) cohort study","volume":"39","author":"Tesfaye","year":"2024","journal-title":"J Gen Intern Med"},{"issue":"3","key":"10.1016\/j.autrev.2025.103864_bb0485","doi-asserted-by":"crossref","first-page":"186","DOI":"10.7326\/M19-2610","article-title":"Assessing the risk for gout with sodium-glucose Cotransporter-2 inhibitors in patients with type 2 diabetes a population-based cohort study","volume":"172","author":"Fralick","year":"2020","journal-title":"Ann Intern Med"},{"issue":"8","key":"10.1016\/j.autrev.2025.103864_bb0490","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.30885","article-title":"Gout flares and mortality after sodium-glucose Cotransporter-2 inhibitor treatment for gout and type 2 diabetes","volume":"6","author":"Wei","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.autrev.2025.103864_bb0495","first-page":"387","article-title":"Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors for recurrent nephrolithiasis among patients with pre-existing nephrolithiasis or gout: target trial emulation studies","author":"McCormick","year":"2024","journal-title":"Bmj-British Med J"},{"issue":"suppl 9","key":"10.1016\/j.autrev.2025.103864_bb0500","article-title":"Risk of incident gout and cardiovascular events within 120 days of incident gout with the use of insulin glargine, glucagon-like Peptide-1 receptor agonists, or sodium-glucose Cotransporter-2 inhibitors in veterans with type 2 diabetes","volume":"76","author":"Amara","year":"2024","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103864_bb0505","first-page":"2","article-title":"Comparative risk of musculoskeletal adverse reactions among new users of dipeptidyl peptidase-4 inhibitors: a retrospective cohort study","author":"Park","year":"2021","journal-title":"Exploratory Res Clin Soc Pharm"},{"issue":"3","key":"10.1016\/j.autrev.2025.103864_bb0510","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1159\/000519008","article-title":"Long-acting glucagon-like Peptide-1 receptor agonist-induced rheumatoid arthritis in a patient with type 2 diabetes mellitus","volume":"27","author":"Kikkawa","year":"2021","journal-title":"Dubai Diabetes Endocrinol J"},{"issue":"4","key":"10.1016\/j.autrev.2025.103864_bb0515","first-page":"673","article-title":"GLP-1 receptor agonist-induced polyarthritis: a case report","volume":"51","author":"Ambrosio","year":"2014","journal-title":"Acta Diabetol"},{"issue":"9","key":"10.1016\/j.autrev.2025.103864_bb0520","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1080\/03007995.2024.2386047","article-title":"The first report of leukocytoclastic vasculitis induced by once-weekly subcutaneous semaglutide","volume":"40","author":"Pinheiro","year":"2024","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"10.1016\/j.autrev.2025.103864_bb0525","article-title":"Semaglutide-induced lupus erythematosus with multiorgan involvement. Cureus journal of","volume":"16","author":"Castellanos","year":"2024","journal-title":"Med Sci"},{"issue":"10","key":"10.1016\/j.autrev.2025.103864_bb0530","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1097\/DAD.0000000000000243","article-title":"Exenatide-induced eosinophil-rich granulomatous panniculitis: a novel case showing injected microspheres","volume":"37","author":"Andr\u00e9s-Ramos","year":"2015","journal-title":"Am J Dermatopathol"},{"issue":"11","key":"10.1016\/j.autrev.2025.103864_bb0535","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1097\/DAD.0000000000000952","article-title":"Exenatide-induced panniculitis: utility of the acid-fast stain to identify injected microspheres","volume":"40","author":"Vidal","year":"2018","journal-title":"Am J Dermatopathol"},{"issue":"11","key":"10.1016\/j.autrev.2025.103864_bb0540","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1007\/s00125-011-2232-3","article-title":"Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis","volume":"54","author":"Hogan","year":"2011","journal-title":"Diabetologia"},{"key":"10.1016\/j.autrev.2025.103864_bb0545","unstructured":"Created in BioRender. Venerito V. 2025."}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997225001247?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997225001247?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,10]],"date-time":"2025-08-10T03:16:30Z","timestamp":1754795790000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997225001247"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":109,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S1568997225001247"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2025.103864","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glucagon-Like Peptide-1 (GLP-1) receptor agonists in rheumatology: A review of current evidence and future directions","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2025.103864","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103864"}}